Inozyme Pharma, Inc. (NASDAQ:INZY) Receives $14.56 Consensus PT from Brokerages

Shares of Inozyme Pharma, Inc. (NASDAQ:INZY - Get Free Report) have received an average rating of "Buy" from the nine ratings firms that are presently covering the stock, Marketbeat.com reports. Nine equities research analysts have rated the stock with a buy rating. The average 12-month target price among analysts that have issued a report on the stock in the last year is $14.56.

INZY has been the subject of a number of research analyst reports. Raymond James reduced their price target on shares of Inozyme Pharma from $24.00 to $12.00 and set an "outperform" rating for the company in a research note on Wednesday, March 12th. HC Wainwright reiterated a "buy" rating and set a $16.00 price target on shares of Inozyme Pharma in a research report on Tuesday, March 11th. Piper Sandler dropped their price objective on Inozyme Pharma from $30.00 to $23.00 and set an "overweight" rating on the stock in a research note on Tuesday, March 11th. Needham & Company LLC decreased their target price on Inozyme Pharma from $23.00 to $15.00 and set a "buy" rating for the company in a research note on Tuesday, March 11th. Finally, Wedbush reiterated an "outperform" rating and issued a $7.00 price target (down from $12.00) on shares of Inozyme Pharma in a research report on Monday, March 10th.

Inozyme Pharma Stock Performance

Inozyme Pharma stock traded down $0.07 during midday trading on Wednesday, reaching $0.92. 562,870 shares of the stock traded hands, compared to its average volume of 495,155. The firm has a fifty day moving average price of $1.22 and a two-hundred day moving average price of $2.91. Inozyme Pharma has a fifty-two week low of $0.91 and a fifty-two week high of $7.80. The firm has a market cap of $59.10 million, a price-to-earnings ratio of -0.59 and a beta of 1.32. The company has a current ratio of 7.68, a quick ratio of 7.68 and a debt-to-equity ratio of 0.51.

Remove Ads

Institutional Trading of Inozyme Pharma

A number of institutional investors have recently bought and sold shares of INZY. abrdn plc acquired a new position in shares of Inozyme Pharma during the 4th quarter worth $472,000. Eventide Asset Management LLC increased its position in Inozyme Pharma by 5.0% during the third quarter. Eventide Asset Management LLC now owns 4,134,436 shares of the company's stock worth $21,623,000 after buying an additional 198,216 shares during the last quarter. Barclays PLC raised its holdings in Inozyme Pharma by 261.4% during the third quarter. Barclays PLC now owns 76,730 shares of the company's stock valued at $401,000 after buying an additional 55,497 shares in the last quarter. Geode Capital Management LLC lifted its position in shares of Inozyme Pharma by 1.7% in the third quarter. Geode Capital Management LLC now owns 1,171,172 shares of the company's stock worth $6,126,000 after buying an additional 19,499 shares during the last quarter. Finally, State Street Corp boosted its stake in shares of Inozyme Pharma by 5.0% during the 3rd quarter. State Street Corp now owns 1,050,420 shares of the company's stock worth $5,494,000 after acquiring an additional 50,386 shares in the last quarter. Institutional investors and hedge funds own 88.30% of the company's stock.

Inozyme Pharma Company Profile

Inozyme Pharma, Inc, a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis.